Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Up After Analyst Upgrade

Aquestive Therapeutics, Inc. (NASDAQ:AQST)’s stock price gapped up prior to trading on Thursday after Lifesci Capital upgraded the stock to a strong-buy rating. The stock had previously closed at $3.95, but opened at $4.29. Aquestive Therapeutics shares last traded at $5.07, with a volume of 10,098,647 shares changing hands.

Several other analysts have also recently weighed in on the company. Zacks Research raised Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $10.14.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock valued at $6,545,000 after buying an additional 276,295 shares in the last quarter. Pale Fire Capital SE raised its holdings in shares of Aquestive Therapeutics by 25.5% during the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after buying an additional 340,767 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Aquestive Therapeutics by 7.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock valued at $3,073,000 after buying an additional 75,275 shares in the last quarter. Sio Capital Management LLC grew its position in Aquestive Therapeutics by 141.9% during the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock worth $3,136,000 after acquiring an additional 555,860 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after acquiring an additional 621,614 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Stock Performance

The firm has a 50-day moving average of $3.98 and a 200-day moving average of $3.24. The firm has a market capitalization of $540.48 million, a P/E ratio of -7.74 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.